BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...on diagnostics innovation to power development of targeted drugs, was the court’s refusal to consider Athena...
...Diagnostics, Inc., et al. v. Mayo Collaborative Services . The court’s decision not to review Athena’s...
...Athena sued the Mayo Clinic, claiming infringement of patents on a diagnostic for myasthenia gravis. Athena...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

...close ties to Asia. At the time, BioNTech declined to divulge the headquarters of Steam Athena...
...in Shanghai. BVCF did not respond to a request for comment. Little information about Steam Athena...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...close ties to Asia. At the time, BioNTech declined to divulge the headquarters of Steam Athena...
...Another series B investor, BVCF Management, is headquartered in Shanghai. Neither Jebsen’s, BVCF’s, nor Steam Athena’s...
...in the prospectus. BioNTech declined to comment, citing a quiet period. Little information about Steam Athena...
BioCentury | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

...Financial Group, Australian firm Platinum Asset Management, Hong Kong’s Jebsen Capital, Europe and Asia-focused Steam Athena...
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...Athena Diagnostics Inc. v. Mayo Collaborative Services LLC were ineligible under Section 101. While the Athena...
...one important similarity: in both cases, claim 1 begins with "A method for treating/diagnosing." " Athena...
BioCentury | May 2, 2019
Financial News

May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

...$175 million in non-dilutive funding from TPG Sixth Street Partners to fund the Phase III ATHENA...
BioCentury | Oct 26, 2018
Financial News

Ahead of Phase II, TP raises $80M mezzanine round

...San Diego, Calif.) raised $80 million in a mezzanine round on Oct. 19 and promoted Athena...
BioCentury | Oct 19, 2018
Financial News

Ahead of Phase II, TP raises $80M mezzanine round

...TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena...
BioCentury | Oct 13, 2018
Product Development

Trevena goes for MOR than morphine

...also prolong QT. Trevena enrolled a broader patient population in its open label Phase III ATHENA...
BioCentury | Jun 27, 2018
Clinical News

Lynparza meets in first-line ovarian cancer

...Clovis Oncology Inc. (NASDAQ:CLVS) expects to begin enrolling patients this half in the Phase III Athena...
Items per page:
1 - 10 of 197
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...on diagnostics innovation to power development of targeted drugs, was the court’s refusal to consider Athena...
...Diagnostics, Inc., et al. v. Mayo Collaborative Services . The court’s decision not to review Athena’s...
...Athena sued the Mayo Clinic, claiming infringement of patents on a diagnostic for myasthenia gravis. Athena...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

...close ties to Asia. At the time, BioNTech declined to divulge the headquarters of Steam Athena...
...in Shanghai. BVCF did not respond to a request for comment. Little information about Steam Athena...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...close ties to Asia. At the time, BioNTech declined to divulge the headquarters of Steam Athena...
...Another series B investor, BVCF Management, is headquartered in Shanghai. Neither Jebsen’s, BVCF’s, nor Steam Athena’s...
...in the prospectus. BioNTech declined to comment, citing a quiet period. Little information about Steam Athena...
BioCentury | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

...Financial Group, Australian firm Platinum Asset Management, Hong Kong’s Jebsen Capital, Europe and Asia-focused Steam Athena...
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...Athena Diagnostics Inc. v. Mayo Collaborative Services LLC were ineligible under Section 101. While the Athena...
...one important similarity: in both cases, claim 1 begins with "A method for treating/diagnosing." " Athena...
BioCentury | May 2, 2019
Financial News

May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

...$175 million in non-dilutive funding from TPG Sixth Street Partners to fund the Phase III ATHENA...
BioCentury | Oct 26, 2018
Financial News

Ahead of Phase II, TP raises $80M mezzanine round

...San Diego, Calif.) raised $80 million in a mezzanine round on Oct. 19 and promoted Athena...
BioCentury | Oct 19, 2018
Financial News

Ahead of Phase II, TP raises $80M mezzanine round

...TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena...
BioCentury | Oct 13, 2018
Product Development

Trevena goes for MOR than morphine

...also prolong QT. Trevena enrolled a broader patient population in its open label Phase III ATHENA...
BioCentury | Jun 27, 2018
Clinical News

Lynparza meets in first-line ovarian cancer

...Clovis Oncology Inc. (NASDAQ:CLVS) expects to begin enrolling patients this half in the Phase III Athena...
Items per page:
1 - 10 of 197